Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.94 -0.3%	$0.99	$0.61 ▼ $5.94	$13.76M	0.08	1.46 million shs	152,475 shs
NEUP Neuphoria Therapeutics	$7.34 +2.2%	$7.45	$2.12 ▼ $12.55	$13.80M	0.53	229,690 shs	7,536 shs
NXTC NextCure	$5.22 +1.8%	$5.23	$2.69 ▼ $19.80	$13.99M	1.25	53,715 shs	13,499 shs
TCRT Alaunos Therapeutics	$1.97 +11.3%	$3.51	$1.31 ▼ $6.20	$4.35M	-0.81	246,416 shs	224,002 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	0.00%	-1.40%	-7.39%	-8.29%	-82.78%
NEUP Neuphoria Therapeutics	0.00%	-11.36%	-15.53%	+5.90%	+717,999,900.00%
NXTC NextCure	0.00%	+0.69%	-16.86%	-15.81%	-73.45%
TCRT Alaunos Therapeutics	0.00%	-21.33%	-37.01%	-33.46%	-37.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	2.3026 of 5 stars	3.5	5.0	0.0	0.6	0.0	0.6
NEUP Neuphoria Therapeutics	1.3034 of 5 stars	3.5	0.0	0.0	0.6	0.0	0.6
NXTC NextCure	4.0803 of 5 stars	3.3	3.0	4.3	0.6	1.7	1.3
TCRT Alaunos Therapeutics	1.0891 of 5 stars	0.0	5.0	0.0	3.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	3.00	Buy	$9.00	856.12% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	186.10% Upside
NXTC NextCure	2.67	Moderate Buy	$25.50	388.51% Upside
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, NEUP, ALLR, and NXTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
NEUP Neuphoria Therapeutics	$10K	1,379.92	N/A	N/A	$15.85 per share	0.46
NXTC NextCure	N/A	N/A	N/A	N/A	$28.06 per share	N/A
TCRT Alaunos Therapeutics	$10K	435.37	N/A	N/A	$1.29 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-173.31%	-102.57%	11/13/2025 (Estimated)
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	11/6/2025 (Estimated)
TCRT Alaunos Therapeutics	-$4.68M	-$2.46	N/A	∞	N/A	N/A	-168.02%	-121.37%	11/12/2025 (Estimated)

Latest TCRT, NEUP, ALLR, and NXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	ALLR Allarity Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	N/A	N/A
8/14/2025	Q2 2025	TCRT Alaunos Therapeutics	-$5.3340	-$0.63	+$4.7040	-$0.63	N/A	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.31	2.31
NEUP Neuphoria Therapeutics	N/A	11.01	11.01
NXTC NextCure	N/A	3.71	3.71
TCRT Alaunos Therapeutics	N/A	3.48	3.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
NEUP Neuphoria Therapeutics	15.90%
NXTC NextCure	42.65%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.01%
NEUP Neuphoria Therapeutics	0.69%
NXTC NextCure	13.30%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	14.62 million	14.62 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A
NXTC NextCure	90	2.68 million	2.32 million	Optionable
TCRT Alaunos Therapeutics	40	2.21 million	1.85 million	No Data

TCRT, NEUP, ALLR, and NXTC Headlines

Recent News About These Companies

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Large Decline in Short Interest

August 18, 2025 | americanbankingnews.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.comF

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, NEUP, ALLR, and NXTC Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$0.94 0.00 (-0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$0.94 0.00 (-0.14%)

As of 04:32 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Neuphoria Therapeutics NASDAQ:NEUP

$7.34 +0.16 (+2.23%)

As of 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

NextCure NASDAQ:NXTC

$5.22 +0.09 (+1.75%)

Closing price 03:49 PM Eastern

Extended Trading

$5.24 +0.02 (+0.38%)

As of 04:04 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Alaunos Therapeutics NASDAQ:TCRT

$1.97 +0.20 (+11.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 -0.01 (-0.76%)

As of 05:29 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time